poh shareholder meeting, page-10

Perhaps someone at the meeting can clarify, but my impression is that the time frame announced (end of June for results) included the multidosing trial.

Of course a new single does trial is needed as I have been pointing out for months. The patch has evolved and there must be a correlation between the single and multi-dose studies that can't be achieved when the patches in the two trials are different designs. The point I am making here is that a single dose trial can be completed in three weeks, not three months.

I have every expectation that by the end of june the Oxypatch will be cleared to start Phase III whenever the company deems appropriate.